MARKET

KIN

KIN

Kindred Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.15
-0.09
-1.09%
After Hours: 8.15 0 0.00% 16:00 12/13 EST
OPEN
8.25
PREV CLOSE
8.24
HIGH
8.53
LOW
8.05
VOLUME
106.24K
TURNOVER
--
52 WEEK HIGH
13.00
52 WEEK LOW
5.96
MARKET CAP
318.54M
P/E (TTM)
-4.9598
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KIN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KIN News

  • Kindred's Mirataz OK'd in Europe
  • seekingalpha.1d ago
  • Kindred Biosciences Reports EC Approval Of Mirataz 20 mg/g Transdermal Ointment for Cats
  • Benzinga.1d ago
  • Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight Loss
  • PR Newswire.1d ago
  • Should You Worry About Kindred Biosciences, Inc.'s (NASDAQ:KIN) CEO Pay Cheque?
  • Simply Wall St..12/06 15:36

More

Industry

Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.08%

Hot Stocks

Name
Price
%Change

About KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
More

Webull offers Kindred Biosciences Inc (KIN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.